Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials
Event summary
- Kelun-Biotech received clinical trial approval from China's CDE for SKB565, its first dual-payload ADC targeting advanced solid tumors.
- SKB565 combines toxins and immunomodulators in a single molecule, aiming to enhance antitumor efficacy through dual mechanisms.
- The drug is developed using Kelun-Biotech's proprietary OptiDC™ platform, representing the company's push into next-generation ADC innovation.
The big picture
Kelun-Biotech's move into dual-payload ADCs reflects broader industry trends toward more complex, multi-mechanism cancer therapies. The company is positioning itself as a leader in next-generation ADC innovation, competing with global players like Seattle Genetics and Roche. Success here could validate its OptiDC™ platform as a key differentiator in the crowded oncology space.
What we're watching
- Clinical Progress
- The pace at which SKB565 advances through clinical trials will determine its commercial potential and competitive positioning.
- Pipeline Strategy
- Whether Kelun-Biotech can sustain momentum in its 'ADC + IO' strategy with additional dual-payload candidates.
- Regulatory Dynamics
- How China's NMPA approval process may influence the global development timeline for SKB565 and similar ADCs.
Related topics